Related Experiment Video

Updated: Aug 16, 2026

A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models
07:49

A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models

Published on: July 21, 2023

Clinical trials in diastolic heart failure

Barry M Massie1, Mary Rose Fabi

  • 1Cardiology Division, San Francisco VAMC, Department of Medicine and Cardiovascular Research Institute, University of California, San Francisco, CA, USA. barry.massie@med.va.gov

Progress in Cardiovascular Diseases
|August 24, 2005
PubMed

Insights

Diastolic heart failure, affecting up to 50% of patients, often occurs in older women and lacks proven treatments. This review examines ongoing trials to improve outcomes for this understudied population.

Area of Science:

  • Cardiology
  • Internal Medicine
  • Clinical Trials

Background:

  • Diastolic heart failure (HFpEF) accounts for 40-50% of chronic heart failure cases.
  • HFpEF predominantly affects older women and is characterized by preserved left ventricular ejection fraction.
  • Left ventricular diastolic dysfunction is a primary driver in most HFpEF cases.

Purpose of the Study:

  • To review recent and ongoing clinical trials in patients with diastolic heart failure.
  • To identify potential therapeutic strategies for heart failure with preserved ejection fraction (HFpEF).
  • To address the lack of evidence-based treatments for HFpEF.

Main Methods:

  • Review of recent and ongoing clinical trials focused on diastolic heart failure.
  • Analysis of patient populations systematically excluded from previous heart failure trials.
  • Synthesis of current research trends in HFpEF treatment.

Main Results:

  • Historically, patients with diastolic heart failure were excluded from major clinical trials.
  • There are currently no universally proven treatments specifically for this patient group.
  • Recent and ongoing trials aim to fill this evidence gap.

Conclusions:

  • Diastolic heart failure represents a significant and growing clinical challenge.
  • Improved understanding and treatment of HFpEF are urgently needed.
  • Ongoing trials offer hope for better therapeutic options and improved patient outcomes.

More Related Videos

Pulsed Wave Doppler Assessment of Diastolic Dysfunction in the ZSF-1 Rat Model of Pulmonary Hypertension Due to Left Heart Disease08:57

Pulsed Wave Doppler Assessment of Diastolic Dysfunction in the ZSF-1 Rat Model of Pulmonary Hypertension Due to Left Heart Disease

Published on: May 22, 2026

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...